Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and beyond

  • Rosati, Giulio
  • Idili, Andrea
  • Parolo, Claudio
  • Fuentes-Chust, Celia
  • Calucho, Enric
  • Hu, Liming
  • Castro Silva, Cecilia de Carvalho
  • Rivas, Luis
  • Nguyen, Emily P.
  • Bergua, José Francisco
  • Álvarez-Diduk, Ruslan
  • Muñoz, Jesús
  • Junot, Christophe
  • Penon, O.
  • Monferrer, Dominique
  • Delamarche, Emmanuel
  • Merkoçi, Arben
The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice., We acknowledge funding from the European Union Horizon2020 Programme under Grant No. 881603 (Graphene Flagship Core 3). We acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacer frente al impacto económico y social del COVID-19 (Ayudas CSIC–COVID-19)”. We acknowledge the MICROB-PREDICT Project for partially supporting the work. The MICROB-PREDICT project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant No. 825694. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. We also acknowledge Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) for the project MAT2017-87202-P. A.I. was supported by a PROBIST postdoctoral fellowship funded by European Research Council (Marie Skłodowska-Curie Grant No. 754510). C.C.C.S. acknowledges funding through CAPES–PRINT (Programa Institucional de Internacionalização; Grant Nos. 88887.310281/2018-00 and 88887.467442/2019-00) and Mackpesquisa-UPM. L.H. acknowledges funding through the China Scholarship Council. ICN2 is funded by the CERCA Programme/Generalitat de Catalunya and supported by the Severo Ochoa programme (MINECO Grant No. SEV-2017-0706).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochromism: An emerging and promising approach in (bio)sensing technology

  • Farahmand Nejad, Mohammad Amin
  • Ranjbar, Saba
  • Parolo, Claudio
  • Nguyen, Emily P.
  • Álvarez-Diduk, Ruslan
  • Hormozi-Nezhad, Mohammad Reza
  • Merkoçi, Arben
Electrochromism (EC) is a unique property of certain materials that undergo an electrochemical-induced change in colouration. During the last decades, electrochromic materials (ECMs) have been applied in a variety of technologies ranging from smart windows to information displays and energy storage devices. More recently, ECMs have attracted the attention of the (bio)sensing community thanks to their ability to combine the sensitivity of electrochemical methods with the intuitive readout of optical sensors. Although still a nascent technology, EC-based sensors are on the rise with several targets (e.g. cancer biomarkers, bacteria, metabolites and pesticides), which have already been detected by (bio)sensors using ECMs as transducers. In this review, we provide the reader with all the information to understand EC and its use in the development of EC-based biosensors., We acknowledge the MICROB-PREDICT project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825694. Financial support from the EU Graphene Flagship Core 2 Project (No. 785219) is also acknowledged. This article reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. ICN2 is funded by the CERCA programme, Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). E.P.N. acknowledges funding through the EU’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 754510.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Toward next generation lateral flow assays: Integration of nanomaterials

  • Sena-Torralba, Amadeo
  • Álvarez-Diduk, Ruslan
  • Parolo, Claudio
  • Piper, Andrew
  • Merkoçi, Arben
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs., We acknowledge financial support to the project AC21_2/00044 (GLEBIOASSAY), funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union, MICROBPREDICT project (European Union Horizon 2020 research and innovation program under grant agreement 825694), and Graphene Flagship Core 3 (European Union Horizon 2020 research and innovation program under grant agreement 881603). ICN2 is funded by CERCA programme, Generalitat de Catalunya. Grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033. The authors also acknowledge the Project PID2021-124795NB-I00 funded by MCIN/AEI/10.13039/501100011033/and FEDER Una manera de hacer Europa and the project PAPYRUS: Grant PLEC2021-007972 funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”. The authors acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacerfrente al impacto económico y social del COVID-19” (Ayudas CSIC-COVID-19). A.S.-T. acknowledges MINECO for the Juan de la Cierva Formación fellowship (FJC2020-043927-I). C.P. acknowledges the Marie Skłodowska-Curie Actions Individual Fellowship; this project received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 795635. C.P. (ISGlobal) also acknowledges support from the Spanish Ministry of Science and Innovation** and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019−2023” Program (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests

  • Castelli, Florence Ane
  • Rosati, Giulio
  • Moguet, Christian
  • Fuentes-Chust, Celia
  • Marrugo-Ramírez, José
  • Lefebvre, Thibaud
  • Volland, Hervé
  • Merkoçi, Arben
  • Simon, Stéphanie
  • Fenaille, François
  • Junot, Christophe
Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine., Christian Moguet is the recipient of a PhD grant funded by CEA. We acknowledge funding from the MICROB-PREDICT project. The MICROB-PREDICT project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825694.